Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable...
Pharmaceutical
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity...
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042...
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour ...
Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug...
A Success Story – DelveInsight’s Strategic Support to a Biopharma Leader in NSCLC Epidemiology Forecasting up to 2034, Segmented by Biomarker Types
In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company specializing in non-small...
Marco Pharma International to Debut at Annual HealCon Event
ROSEBURG, Ore., April 24, 2025 /PRNewswire/ -- Marco Pharma International, a leading provider of German homeopathic and herbal remedies, will participate...
NexusTek Expands Secure by Design Solutions to Accelerate Innovation in Life Sciences
Leading managed service provider deepens capabilities to advance R&D, improve time-to-market, and ensure regulatory compliance DENVER, April 24, 2025 /PRNewswire/...
Abu Dhabi Pioneers Collaborative Approach to Responsible AI in Healthcare at Health Leaders Roundtable
Held during Abu Dhabi Global Health Week, the roundtable united global health leaders to shape a Declaration on AI governance...
Occam Health Services Announces Expansion to Plano, TX Area
Additional space underscores commitment to innovative patient support service offerings, powered by Cloud Script™ technology platform STERLING, Va., April 24,...
Aily Labs Expands Board and Advisory Board with AI and Industry Heavyweights to Accelerate Agentic AI Adoption Across the Fortune 500
Aily Labs welcomes Amy Chang, a technology visionary and current board member of Disney and Procter & Gamble, to its...
Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
NASHVILLE, Tenn., April 24, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global provider of supply...
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation...
Inmagene Reports Topline Results from Phase 2a Study of IMG-007, a Nondepleting Anti-OX40 Monoclonal Antibody with an Extended Half-life, in Patients with Alopecia Areata
Treatment with three doses of 300 mg (Cohort 1) and 600 mg (Cohort 2) IMG-007 over four weeks resulted in...
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged...
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people...
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology
April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder...
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused...
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025
STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter...